India’s Lupin Aims For U.S. Branded Drug Buys To Break Generics Reliance
This article was originally published in PharmAsia News
Executive Summary
Lupin’s billionaire President Nilesh Gupta plans to shed some of his company’s generics risks by buying profitable U.S.-made branded drugs, particularly treatments for skin diseases and infections.